Encorafenib in combination with Cetuximab in BRAFV600E–Mutated Metastatic Colorectal Cancer: A European pooled analysis of observational studies
Encorafenib in combination with Cetuximab in BRAFV600E–Mutated Metastatic Colorectal Cancer: A European pooled analysis of observational studies
Encorafenib in combination with Cetuximab in BRAFV600E–Mutated Metastatic Colorectal Cancer: A European pooled analysis of observational studies
Encorafenib in combination with Cetuximab in BRAFV600E–Mutated Metastatic Colorectal Cancer: A European pooled analysis of observational studies
Status
Status :
Completed
Type of study
RWE
Min. Age
18
Years old
Max. Age
-
Gender
All
Therapeutic area :
Oncology
Disease :
BRAFV600E - mutant metastatic colorectal cancer
Study medication :
Encorafenib (BRAFTOVI®)
Phase :
RWE
Start Date :
01 January 2020
End Date / Planned study Completion Date :
31 October 2024
Sponsor(s) or Co-Sponsor(s) :
- Association des gastro entéroloques oncologues (AGEO)
- Stichting Dutch colorectal cancer group (DCCG)
- GONO foundation (GONO)
- Grupo de tratamiento de los tumores digestivos Spanish cooperative group for the treatment of digestive tumours (TTD)
Access to Lay Protocol Synopsis
Access to Results Lay Summary
Publication
Send by email